Colesevelam

Introduction Overview

Generic Name

colesevelam

Brand Name

Welchol

Dosage Form

Oral tablets and oral powder for suspension

Drug Class

Bile acid sequestrants

Pharmacokinetics

Absorption:
Colesevelam exhibits negligible systemic absorption when administered orally. This characteristic is typical of bile acid sequestrants, as they act locally within the gastrointestinal tract. The lack of systemic absorption minimizes systemic side effects and reduces the potential for systemic drug interactions. Because it remains within the gut lumen, colesevelam's therapeutic effects are localized to binding bile acids in the intestine.

Distribution:
Since colesevelam is not absorbed into the systemic circulation, traditional pharmacokinetic measures of distribution do not apply. The drug binds bile acids in the intestinal lumen forming insoluble complexes that are excreted in feces. This sequestration interrupts the enterohepatic circulation of bile acids, effectively depleting the bile acid pool.

Metabolism:
Colesevelam is not metabolized by hepatic or extrahepatic enzymes because it does not enter systemic circulation. Its mechanism relies entirely on physical binding of bile acids in the gastrointestinal tract rather than biochemical metabolism. This characteristic contributes to the drug's safety profile and minimal systemic toxicities.

Elimination:
The complex of colesevelam bound to bile acids is eliminated via fecal excretion. The formed resin-bile acid complex is insoluble and passes through the digestive tract without absorption. The elimination process is passive and reflects the natural fecal excretion of bile salts, typically occurring within hours according to gastrointestinal transit time. No renal elimination or hepatic clearance is relevant for colesevelam.

Dosage Forms

Available Dosage Forms:
Welchol is available as oral tablets and as an oral powder for suspension. The tablets are film-coated and designed to be swallowed whole with food and liquid. The oral powder is provided in packets and must be mixed with liquids prior to ingestion to facilitate dosing, especially in patients who have difficulty swallowing tablets.

Specific Dosage Forms Include:
- Oral tablets: 625 mg each
- Oral powder for suspension: Each packet contains enough powder to be mixed with 8 ounces (approximately 240 mL) of water, fruit juice, or diet soda for administration

Dosages for Adults and Adolescents:
- For hyperlipidemia and primary elevations of LDL cholesterol: The typical adult dose is 3.75 grams daily, which corresponds to 6 tablets once daily or 3 tablets twice daily.
- Alternatively, doses may be given as the powder formulation as 3.75 grams once daily or in divided doses.
- For adjunct treatment of type 2 diabetes mellitus (to improve glycemic control): The same dosing regimens as for hyperlipidemia apply.
- In adolescents age 10 and older: Use of Welchol is similarly dosed with clinical monitoring; however, it is not recommended for children under 10 years.

Specific Patient Populations:
- Pediatric use is limited; Welchol is approved for children aged 10 years and older for hyperlipidemia.
- Elderly patients do not require dose adjustments based on existing data.
- Patients with hepatic impairment do not require dose adjustment, but caution is advised if bile acid metabolism is severely altered.
- Due to the polymeric resin nature and local GI effects, no dosage adjustments are typically necessary for renal impairment.
- Powder formulation containing phenylalanine should be used cautiously in patients with phenylketonuria (PKU).

Mechanism Of Action

Colesevelam, the active component of Welchol, functions as a bile acid sequestrant. Its primary molecular mechanism involves binding bile acids in the small intestine, forming an insoluble complex that prevents their reabsorption via enterohepatic circulation. By interrupting the normal recycling of bile acids, colesevelam effectively depletes the bile acid pool.

This reduction in bile acids triggers hepatocytes to convert more cholesterol into bile acids to replenish the pool, subsequently lowering hepatic cholesterol levels. This upregulation leads to increased expression of LDL receptors on hepatocyte surfaces, enhancing uptake and clearance of low-density lipoprotein cholesterol (LDL-C) from the bloodstream. Thus, colesevelam indirectly lowers circulating LDL cholesterol levels, which reduces the risk of atherosclerosis and cardiovascular events.

In addition to its lipid-lowering effects, colesevelam has demonstrated efficacy in improving glycemic control in adults with type 2 diabetes mellitus. The precise cellular pathways for this glucose-lowering effect are not completely understood but may involve modulation of bile acid signaling through receptors such as the farnesoid X receptor (FXR) and the G protein-coupled bile acid receptor TGR5. Activation of these receptors can influence glucose metabolism by altering gluconeogenesis, insulin sensitivity, and incretin hormone secretion, contributing to reductions in fasting plasma glucose and hemoglobin A1c levels.

Unlike other bile acid sequestrants, colesevelam shows a higher affinity for bile acids, which enhances its efficacy at lower doses and with fewer side effects. Comparative clinical studies have shown that colesevelam has improved tolerability and lipid-lowering capacity compared to older resins like cholestyramine and colestipol. Moreover, its non-absorbed polymeric nature minimizes systemic adverse events and drug interactions, favoring its use in combination therapies with statins and oral antidiabetic drugs.

Pharmacological Actions

Binds bile acids in the intestine to prevent their reabsorption.
Lowers plasma LDL cholesterol by increasing hepatic clearance.
Reduces total cholesterol and apolipoprotein B levels.
Improves glycemic control in type 2 diabetes mellitus patients.
Modulates bile acid receptor signaling pathways (FXR and TGR5).
Does not significantly alter triglyceride levels but may increase triglycerides in some patients.
Exhibits minimal systemic absorption, limiting systemic toxicity.
Can be used as an adjunctive therapy with statins for enhanced lipid lowering.
Acts locally within the gastrointestinal tract.
Increases the hepatic conversion of cholesterol to bile acids.
Reduces risk factors associated with atherosclerosis and cardiovascular disease.
Improves hemoglobin A1c and fasting glucose levels in diabetic patients.
Demonstrates better tolerability compared to older bile acid sequestrants.

Therapeutic Or Clinical Uses

Treatment of primary hyperlipidemia to lower elevated LDL cholesterol.
Adjunct therapy in combination with statins for enhanced cholesterol lowering.
Improvement of glycemic control in adults with type 2 diabetes mellitus.
Reduction of cardiovascular risk factors by lowering LDL cholesterol.
Use in pediatric patients (10 years and older) for hypercholesterolemia management.
Adjunct to diet and exercise programs for cholesterol and glucose management.
Potential off-label use to manage dyslipidemia when statins are contraindicated.
May be used in patients intolerant to statin therapy for LDL reduction.
Favorable option for patients concerned about systemic drug interactions.
Treatment of hyperlipoproteinemia type IIa (familial hypercholesterolemia).
Part of a comprehensive treatment plan including lifestyle modifications.

Side Or Adverse Effects

Constipation, the most common adverse effect due to resin nature.
Nausea and gastrointestinal discomfort including upset stomach.
Abdominal pain and bloating.
Rare risk of pancreatitis, particularly in patients with elevated triglycerides.
Possible increases in serum triglyceride levels.
Flatulence and indigestion.
Potential for bowel obstruction in patients with pre-existing GI tract issues.
Allergic reactions including rash, urticaria, or angioedema in rare cases.
Esophageal obstruction if tablets are not swallowed properly.
Vitamin deficiencies (A, D, E, K) with long-term use due to interference with fat-soluble vitamin absorption.
Rare reports of diverticulitis exacerbation.
May cause temporary elevation of liver enzymes.
Rare drug-induced nutrient malabsorption leading to deficiencies.
Possible interaction leading to decreased absorption of co-administered oral medications.

Precautions

Avoid use in patients with elevated triglycerides above recommended thresholds.
Use cautiously in patients with history of bowel obstruction or GI motility disorders.
Ensure adequate hydration to help minimize constipation.
Monitor triglyceride levels regularly to prevent pancreatitis risk.
Assess for vitamin A, D, E, and K deficiencies during prolonged therapy.
Avoid in patients with known hypersensitivity to colesevelam or components of the formulation.
Consult doctor before use if history of dysphagia or swallowing difficulties.
Use in pediatric patients only from age 10 and older; safety in younger children not established.
Inform healthcare provider of other concurrent medications to manage potential absorption issues.
Not recommended for patients with diabetic ketoacidosis.
Patients with phenylketonuria should be cautious with the powder formulation due to phenylalanine content.
Pregnant or breastfeeding women should consult healthcare provider before use.
May interfere with absorption and efficacy of oral contraceptives and warfarin; dose timing adjustments recommended.
Advise patient to not discontinue statins or other cholesterol medications without consulting a physician.
Advise patients to adhere to dietary recommendations to prevent GI side effects.

Warnings

Contraindicated in patients with bowel obstruction or history of bowel obstruction.
Do not use in patients with triglyceride levels >500 mg/dL due to risk of pancreatitis.
Not to be used in diabetic ketoacidosis management.
Risk of severe constipation leading to bowel obstruction; discontinue if severe constipation develops.
Potential for pancreatitis, especially if triglycerides increase during therapy.
Do not use in children under 10 years of age.
Caution in patients with swallowing difficulties or GI strictures.
May interfere with absorption of other medications leading to reduced efficacy.
Avoid use in patients with hypersensitivity to any component of Welchol.
Patients should be monitored for vitamin deficiencies with long-term treatment.
Not a substitute for diet and exercise; should be used as part of comprehensive therapy.
Immediate medical attention required if signs of allergic reaction develop (e.g., hives, swelling, difficulty breathing).
Avoid abrupt discontinuation without medical supervision.
Not effective for lowering triglycerides and may increase triglyceride levels.

Contraindication

Hypersensitivity to colesevelam or any component of the formulation.
History of bowel obstruction or gastrointestinal obstruction.
Severe hypertriglyceridemia: triglyceride levels >500 mg/dL.
History of pancreatitis caused by high triglycerides.
Diabetic ketoacidosis.
Children under 10 years of age due to insufficient safety data.
Patients unable to swallow tablets and who cannot tolerate the powder form.
Patients with phenylketonuria (PKU) should avoid the powder formulation containing phenylalanine.
Use deferred in patients with known severe GI motility disorders.
Known malabsorption syndromes affecting fat-soluble vitamins without monitoring.

Drug Interactions

Colesevelam can reduce absorption of cyclosporine; administer cyclosporine at least 4 hours before Welchol.
Reduces absorption of olmesartan; separate dosing by at least 4 hours.
May interfere with absorption of phenytoin; stagger dosing.
Decreases effectiveness of levothyroxine and other thyroid hormones; administer thyroid meds at least 4 hours before Welchol.
May reduce efficacy of oral contraceptive pills; take contraceptives 4 hours prior.
Decreased absorption of multivitamins and fat-soluble vitamins necessitates monitoring.
Warfarin absorption may be affected; monitor INR closely.
Oral diabetes medications such as chlorpropamide, glimepiride, glipizide, glyburide, tolazamide, and tolbutamide should be taken 4 hours prior to Welchol to prevent decreased absorption.
Reduced bioavailability for some drugs due to binding in the GI tract.
May affect absorption of digoxin, but clinical significance is variable; monitoring recommended.
Interference with absorption of other concomitant medications especially those with narrow therapeutic indices.
Patients advised to take other oral medications at least 4 hours prior to Welchol to minimize interactions.
Other drugs not specifically studied may also have absorption affected; clinical vigilance required.
No systemic metabolic drug interactions due to negligible absorption of colesevelam.
Herbal products and over-the-counter supplements may also be affected.

Preparations Of The Drug

Welchol tablets: 625 mg film-coated tablets intended for oral administration.
Welchol oral powder: packets containing powder to be suspended in liquids (water, fruit juice, or diet soda) for oral intake.
Powder contains phenylalanine; contraindicated or used cautiously in patients with phenylketonuria (PKU).
Tablets should be swallowed whole with a meal and adequate liquid to reduce risk of esophageal obstruction.
Powder should be mixed immediately before use and consumed right away, with a second glass of liquid to ensure complete ingestion.
Shelf-stable formulations stored at room temperature away from moisture and heat.
Both formulations require administration with meals to maximize bile acid binding efficacy.
Dosage forms designed to provide flexibility for patients with swallowing difficulties and those preferring powder over tablets.
Packaging includes patient instructions emphasizing adequate hydration and timing with concomitant medications.
Available as branded Welchol; generic colesevelam formulations may exist but should be verified for equivalence.
Oral powder provides an alternative for pediatric patients who cannot swallow tablets.
Formulation engineered to sustain bile acid binding capacity throughout intestinal transit.
Non-absorbed polymeric resin structure that is chemically resistant to gastrointestinal enzymatic degradation.
Available only for oral administration; no injectable or other dosage forms currently approved.
Approved for use as monotherapy or adjunctive therapy in combination with other lipid- or glucose-lowering agents.